KALA BIO NASDAQ:KALA said on Monday it will stop developing its experimental treatment for a type of eye disease after it failed to meet the main goal in a mid-stage study.
KALA BIO scraps development of eye disease drug after trial failure
Earlier from Kala Bio
- KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
- KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
- KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
- KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Later from Kala Bio
- KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
- KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- KALA BIO Settles Approximately $10.6 million of Debt
- KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
- Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
Follow Kala Bio into a list and get an email when it puts out news.
Follow Kala Bio